COMPANY

Nuvig Therapeutics

HQ: Palo Alto, CA source · nuvigtx.com ↗ · West Coast

Keywords: immunology autoimmune diseases autoimmune disease Chronic Inflammatory Demyelinating Polyneuropathy Immune Thrombocytopenia NVG-2089

Location: Palo Alto, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series B · $161M · announced Dec 5, 2024 Company release ↗
Source quote
- Dec 5, 2024 · Company release ↗
  “Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel”

Raises announced in these releases: $161M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Sep 30, 2025 Trial start Phase 2: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia source ↗
Apr 25, 2025 Trial start Phase 2: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP source ↗
Dec 5, 2024 Raise Private equity round — Series B: $161M (total, as published), announced Dec 5, 2024. Source: company's own press page. source ↗
Dec 5, 2024 Raise Series B · $161M source ↗

Jun 30, 2027 (ESTIMATED) · Phase 2 · Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia · NCT07095127

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $161.0M. Last 2 years.

Dec 5, 2024 Private equity round — Series B: $161M (total, as published), announced Dec 5, 2024. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07027111	Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP	Phase 2	Terminated	Apr 25, 2025	Oct 1, 2026 (actual)
NCT07095127	Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia	Phase 2	Recruiting	Sep 30, 2025	Jun 30, 2027 (estimated)